NCT01182610View on ClinicalTrials.gov

Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Gastroesophageal AdenocarcinomaAdenocarcinoma of the Distal EsophagusAdenocarcinomas of the Gastroesophageal JunctionAdenocarcinoma of the Proximal Stomach
Interventions
DRUG

Panitumumab

Panitumumab 9mg/kg on Days 1, 22, and 43

DRUG

Paclitaxel

Paclitaxel 200mg/m2 on Days 1 and 22

DRUG

Carboplatin

Carboplatin AUC=6 on Days 1 and 22

DRUG

5FU

5FU 225mg/m2/day on Days 1-15 and 22-36

Trial Locations (1)

72401

Clopton Clinic, Jonesboro

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Accelerated Community Oncology Research Network

OTHER